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Infectiveendocarditisisalife-threateningillness.
Staphylococcus aureus is a common cause of
endocarditis with an increasing number ofcases
caused by methicillin resistant s. aureus.
CASEREPORT A 66-year-old male with early
gastric carcinoma underwent distal gastrectomy
withretrocolicRoux-en-ygastrojejunostomy. He
hadnosignificantpriorcardiachistory. Hisinitial
post-operative course was uncomplicated but
delayed gastric emptying due to obstruction at
the anastamosis led to elective central line
insertion for total parenteral nutrition on the
eighth post-operative day.
After the indwelling central catheter had been
present for 10 days, the patient deteriorated. He
became pyrexial with a temperature of 400C,
tachycardic, with leucocytosis of 24.7 x 109/1
(normal4-10)andhehadmicroscopichaematuria.
Blood cultures were taken and the central line
was removed empirically. Urine culture was
positive for pseudomonas and this was initially
presumed to be the source of sepsis.
Pyrexiacontinueddespiteintravenousantibiotics.
After 72 hours the first blood culture confirmed
bacteraemia with methicillin resistant
staphylococcus aureus (MRSA) and at 96 hours
the central line tip also cultured MRSA. These
isolates were sensitive tovancomycin whichwas
subsequently given intravenously (therapeutic
levels were maintained with a dose of 1.2-1.5 g
once daily). Pyrexia persisted but there was no
cardiacfailureordocumentationofanewmurmur.
Six days after presentation the patient
coincidentally developed chest pain and
congestivefailure.Acardiologyconsultationwas
requested. At this point a new mitral regurgitant
murmur was detected. The diagnosis of
endocarditiswasestablishedonbothtransthoracic
and transoesophageal echocardiogram which
confirmed mild mitral regurgitation and showed
multiple anterior leaflet vegetations (see figures
laandlb).Repeatbloodculturesremainedpositive
for MRSA, C-reactive protein was 154 mg/l
(normal 0-10); ESR was 115 mm/hour and the
white cell count was 17.42 x 109/l.
Figure Ja. Transoesophageal image showing a large
vegetation(V) attachedtotheanteriorleaflet
of the mitral valve, prolapsing into the left
atrium (LA) at end systole. The relatively
echolucent area(P) represents aperforation
in the anteriorleaflet. LVrepresents the left
ventricle.
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Figure lb. WithcolourDopplerapplied,thereis severe
mitral regurgitation filling the left atrium.
At mitral valve level there are two distinct
regurgitantjets, onethroughthevalveorifice
(MRo) and the other through the anterior
leaflet perforation (MRp).
After maximal therapy with vancomycin and
fusidic acid (500 mg 8 hourly IV) there was little
improvement. Repeat transoesophageal
echocardiography revealed progressive valve
destruction, therewas severemitralregurgitation
and anterior leaflet perforation. The patient was
transferred to a tertiary referral centre with a
cardiac surgical unit. Prior to cardiac surgery he
had received a total of 44 days of intravenous
vancomycin. The initial fusidic acid therapy was
later changed to rifampicin. This was initially
given orally (300 mg t.i.d. for 2 weeks) and then
administered intravenously (600mg daily) inthe
/
Figure 2. H & E stain (original magnification lOx).
The surfaceofthe valve cusp shows clumps
ofdark staining bacteria. The top righthand
of the picture shows an inflammatory
exudate. The valve cusp is hyalinised and
there is an area of necrosis.
peri-operative period. Despite the aggressive
antimicrobial therapy the inflammatory indices
remainedgrosslyelevated.Thepatientunderwent
mitralvalvereplacementwithaSt.Judesmedical
prosthesis on the 57th day after initial gastric
surgery.
Histopathology of the excised valve revealed
largecoloniesofgrampositivecocciwithnecrosis
of the valve substance and confirmation of the
leaflet perforation which had been diagnosed
echocardiographically (seefigure 2). Antibiotics
were stopped post-operatively on day 5. The
patient subsequently made a full recovery and
has had no recurrence of his gastric malignancy
to date.
DISCUSSION
Staphylococcal endocarditis has long been
recognised as an aggressive and rapidly
progressive disease. Overthepast 10years, there
has been a consistentrise in the incidence ofthis
illness inlinewithbothcommunity-acquired and
hospital-acquired s. aureus bacteraemia. Indeed
s. aureus (andincreasinglyMRSA) is now oneof
the most common infective agents in hospital-
acquired native valve endocarditis.1 This
conditionisknowntocarrybothahighmorbidity
and mortality. It should always be considered in
the differential diagnosis for ill patients with
persistent fever, and repeatedly positive blood
cultures for coagulase-positive staphylococci.
This is particularly the case in the presence of
established risk factors for bacteraemia such as
central venous line, peripheral venous line and
arterio-venous fistula.
Features that occur more commonly in
staphylococcal infection includepersistent fever
beyond seven days (but this may also reflect
complications), haematuria, embolic events,
neurological involvement and pronounced
elevation of ESR and C-reactive protein (often
>150).2 Echocardiographic data should be
obtained early with transoesophageal imaging
being mandatory in a suspicious case not
confirmed by transthoracic views. The Duke
criteria have been reported to have a negative
predictive value of98% and shouldbe applied to
assist the diagnosis.'
The clinical course in this case was consistent
with a typical s. aureus endocarditis. The large,
friable and mobile vegetations were obvious on
both transthoracic and transoesophageal
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echocardiography. The early and progressive
valve dysfunction, with persistence of the
organism at histopathology, confirms the
destructive and virulent nature ofthis infection.
Activeinfectioncontinueddespiteprolongeduse
oftherapeutic agents to which the organism was
sensitive.
Empirical treatment for methicillin sensitive
bacteria is a semi-synthetic penicillin for 4-6
weeks plus gentamicin in the initial 5-7 days of
therapy. Whenmethicillinresistanceissuspected
or confirmed, intravenous vancomycin remains
the current treatment of choice. Additional
rifampicinand/orgentamicinhavenotbeenshown
to improve curerates, although adjuvant therapy
is always recommended.4'5 However, with the
gradual emergence of vancomycin resistance in
MRSAoverthelastyear, management ofsimilar
infections may become increasingly difficult.
Isolates of glycopeptide intermediate s. aureus
(GISA) which do not respond to vancomycin or
teicoplanin in vivo have now been isolated in
boththeUnited States andJapan. This bacterium
has been demonstrated to have an abnormally
high minimal inhibitory concentration (MIC) of
vancomycinwhichisprobablydueto anincrease
in extracellular material. The most likely
explanation is that the methicillin resistant
organisms have undergone cellularmodification
as a result of prolonged exposure to
vancomycin.6'7 The authors suggest that
quantitative assessment ofMIC forglycopeptide
resistance, infection control and active
surveillance becomes mandatory. Combination
therapywithampicillin/sulbactam andarbekacin
has effectively treated the organism in a case of
pneumonia.
Thetimingofsurgicalinterventioninendocarditis
has been controversial and in individual cases
remains a difficult decision. At present the
American Heart Association advise consultation
with a cardiac surgeon as soon as a diagnosis of
aorticormitralvalveendocarditisismade.Present
indications for surgery include acute valvular
regurgitation with heart failure, fungal
endocarditis, annular or aortic abscess, valve
dysfunction with persistent infection despite
appropriate treatment, recurrent emboli, mobile
vegetations >10 mm, early mitral infection
amenable to repair and persistent pyrexia with
leucocytosis despitenegativebloodcultures. Pre-
operative LV ejection fraction of >50%o is
associated with better survival.8
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Surgical options abound, including homograft in
active infection,9 early radical surgery with
mechanical prosthesis in staphylococcal
infection,'0andvalvereplacementaftertheacute
infection has settled. A highly co-ordinated
approachwithearlyinvolvementofacardiologist,
acardiac surgeonandabacteriologistisessential
to optimise the outcome ofMRSA endocarditis.
With best current management, native valve
staphylococcal endocarditis has been reported to
carry a mortality of almost 50% in some series.
The severe nature of this disease places even
greater emphasis on the need for prevention and
earlydetection. Anysiteofbacterialaccessshould
be kept fastidiously aseptic, particularly central
venous cannulae. The diagnosis of infective
endocarditis should be both considered and
established early, as opposed to being one of
exclusion. As drug resistance increasingly limits
chemotherapeutic options, more aggressive
surgical strategies may become necessary. The
role of surgery may have to be redefined and
early routine intervention adopted, if antibiotic
resistance evolves more rapidly than drug
development.
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